F. Hoffmann-La Roche v A. Menarini Diagnostics (CFI, 1 October 2025)
| Date | 1 October 2025 |
|---|---|
| Court | CFI |
| Division | Düsseldorf (DE) Local Division |
| Type of action | Application RoP262A |
| Case number(s) | UPC_CFI_712/2025 |
| Registry reference | UPC_CFI_712/2025 |
| Parties | F. Hoffmann-La Roche AG a.o. v. A. Menarini Diagnostics S.r.l. a.o. |
Official decision (PDF) · UPC registry entry
Case timeline
- 5 December 2025 : F. Hoffmann-La Roche v A.Menarini Diagnostics (CFI, 5 December 2025) UPC_CFI_712/2025
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In an order of 1 October 2025 (UPC_CFI_712/2025), issued in German, the Düsseldorf Local Division protected under Rule 262A the confidential information contained in the objection filed on 23 September 2025 by the Menarini companies against Roche (EP 1 962 668): the manufacturing process of the accused products, negotiations with the manufacturer Sinocare, prices and margins, and the unredacted versions of three written witness statements. The order was uncontested. Its interest lies in the clarification given for knowledge acquired outside the proceedings.
Question
Which information in the objection should be restricted to a limited circle, and how should persons who already knew of it be treated?
Decision
The formal requirements of Rules 262A.2 and 262A.3 were met and the applicants’ representatives were heard (paragraph 2), they did not contest the classification (paragraph 3), and the parties agreed on the circle of authorised persons (paragraph 5). On Roche’s side, access is limited to representatives, witnesses and experts and to four named members of its in-house IP teams, and the duty of confidentiality survives the proceedings. The division clarified that the bar on use does not cover information already known to certain persons outside the proceedings (paragraph 6), and left the hearing, the decision and third-party access to be addressed later (paragraph 7). Any culpable breach may attract a penalty payment.
Key points for practice
- The legal basis combines Article 58 UPCA, Rule 262A and Article 9 of the Trade Secrets Directive (EU) 2016/943 (paragraph 1).
- A party confronted with information it already knew should have the corresponding exception spelt out in the order.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 58
- Rules of Procedure
- Rules 262.2 and 262A
- Other provisions
- Directive (EU) 2016/943, Art. 9(1) and (2)(a)
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Confidentiality club.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantF. Hoffmann-La Roche AG a.o3 decisions in the corpusFollow this party
- defendantA. Menarini Diagnostics S.r.l. a.o3 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 1 October 2025 F. Hoffmann-La Roche v A. Menarini Diagnostics (CFI, 1 October 2025) Application RoP262A · UPC_CFI_712/2025
- 5 December 2025 F. Hoffmann-La Roche v A.Menarini Diagnostics (CFI, 5 December 2025) Application for provisional measures · UPC_CFI_712/2025
La demande est accueillie pour l'essentiel : la contrefaçon littérale des revendications 1 et 16 est suffisamment certaine, la validité suffisamment assurée et l'urgence établie, la division prononce une injonction couvrant la fabrication, la remise des produits à un huissier et des informations, sans garantie, les fra…
- 11 March 2026 A. Menarini Diagnostics v F. Hoffmann-La Roche (CoA, 11 March 2026) Appeal RoP220.1 · appeal, first-instance number cited in the decision
La cour d'appel autorise le désistement de la demande de mesures provisoires de Roche après transaction, déclare la procédure close, annule l'audience du 18 juin 2026 et ne statue pas sur les frais, conformément à l'accord des parties.
What the record states
- Nature of the act
- Application RoP262A
- Outcome (Dhenne Avocats summary)
- La division réserve à un cercle restreint les informations confidentielles de l'opposition des défenderesses, avec l'accord des parties, et précise que l'interdiction d'usage ne vise pas les informations déjà connues hors de la procédure.
- Appeal
- An appeal is documented in the corpus (see above).
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 1 962 668mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- F. Hoffmann-La Roche v A.Menarini Diagnostics (CFI, 5 December 2025) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 1 962 668 | Mentioned in the analysis (role not qualified) Also mentioned in 3 other decision(s): F. Hoffmann-La Roche v A. Menarini Diagnostics (CFI, 25 March 2026) · A. Menarini Diagnostics v F. Hoffmann-La Roche (CoA, 11 March 2026) · F. Hoffmann-La Roche v A.Menarini Diagnostics (CFI, 5 December 2025) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.